SAR443579 / Sanofi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAR443579 / Sanofi
NCT06508489: A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

Recruiting
1/2
18
US, RoW
SAR443579, venetoclax, VENCLYXTO / VENCLEXTA, azacitidine
Sanofi
Acute Myeloid Leukemia
02/29
02/29
TCD17197, NCT05086315 / 2021-004287-98: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Recruiting
1/2
169
Europe, US, RoW
SAR443579
Sanofi
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
12/25
10/30

Download Options